2 years ago
MRNA
AnalystsMani ForooharMani Foroohar's Stock Forecasts
AnalystsMani Foroohar
Sectors:
Analyst Ranking
Bottom 2%
#4499 out of 4560 analysts
Average Return
-10.78%
Win Rate
46%45 out of 98
Risk vs Reward
Poor
Good
Mani Foroohar's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Bridgebio Pharma IncBBIO | +346.48% | $8.52 | $38.04 | 2023-01-22 - 2024-01-22 | Buy |
Bridgebio Pharma IncBBIO | +250.59% | $9.29 | $32.57 | 2022-07-25 - 2023-07-25 | Buy |
Tenaya Therapeutics IncTNYA | +136.70% | $1.88 | $4.45 | 2023-11-29 - 2024-04-23 | Buy |
Rocket Pharmaceuticals IncRCKT | +104.86% | $10.70 | $21.92 | 2022-05-19 - 2023-05-19 | Buy |
Amryt Pharma PLCAMYT | +104.65% | $7.09 | $14.51 | 2022-03-09 - 2023-01-09 | Buy |
Mani Foroohar Analyst Color
Get additional color on Mani Foroohar's coverage of popular stocks
Mani Foroohar's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Mirum Pharmaceuticals IncMIRM | 10 | Buy | $43.00 | +76.09% | Maintains | a month ago |
Engene Holdings IncENGN | 1 | Buy | $31.00 | +103.15% | Initiates Coverage On | 2 months ago |
Allovir IncALVR | 9 | Hold | $1.00 | +26.42% | Downgrades | 4 months ago |
Wave Life Sciences LtdWVE | 4 | Buy | $12.00 | +136.22% | Upgrades | 4 months ago |
Tenaya Therapeutics IncTNYA | 1 | Buy | $7.00 | +57.30% | Initiates Coverage On | 5 months ago |
Lexeo Therapeutics IncLXEO | 1 | Buy | $19.00 | +56.51% | Initiates Coverage On | 5 months ago |
Curevac NvCVAC | 1 | Buy | $13.00 | +400.00% | Initiates Coverage On | a year ago |
Arrowhead Pharmaceuticals IncARWR | 10 | Hold | $40.00 | +68.21% | Downgrades | a year ago |
Bridgebio Pharma IncBBIO | 11 | Buy | $27.00 | N/A | Maintains | a year ago |
4d Molecular Therapeutics IncFDMT | 7 | Hold | $13.00 | N/A | Maintains | a year ago |
Decibel Therapeutics IncDBTX | 5 | Hold | $2.00 | N/A | Downgrades | a year ago |
Moderna IncMRNA | 16 | Sell | $93.00 | N/A | Downgrades | a year ago |
Ionis Pharmaceuticals IncIONS | 11 | Hold | $27.00 | N/A | Maintains | a year ago |
Recursion Pharmaceuticals IncRXRX | 6 | Hold | $8.00 | N/A | Maintains | a year ago |
Regenxbio IncRGNX | 6 | Hold | $14.00 | N/A | Maintains | a year ago |
Rocket Pharmaceuticals IncRCKT | 9 | Buy | $49.00 | N/A | Maintains | a year ago |
Intellia Therapeutics IncNTLA | 4 | Buy | $84.00 | N/A | Maintains | a year ago |
Editas Medicine IncEDIT | 4 | Hold | $7.00 | N/A | Maintains | a year ago |
Bluebird Bio IncBLUE | 7 | Hold | $8.00 | N/A | Maintains | a year ago |
Beam Therapeutics IncBEAM | 2 | Buy | $77.00 | N/A | Maintains | a year ago |
Alnylam Pharmaceuticals IncALNY | 8 | Hold | $143.00 | N/A | Maintains | a year ago |
Amryt Pharma PLCAMYT | 6 | Hold | $14.50 | N/A | Downgrades | a year ago |
Lenz Therapeutics IncLENZ | 4 | Hold | $2.00 | N/A | Downgrades | a year ago |
Abeona Therapeutics IncABEO | 5 | Hold | $6.00 | N/A | Maintains | a year ago |
Crispr Therapeutics AgCRSP | 1 | Buy | $76.00 | N/A | Maintains | a year ago |
Tourmaline Bio IncTRML | 5 | Hold | $2.00 | N/A | Maintains | 2 years ago |
Caribou Biosciences IncCRBU | 4 | Buy | $34.00 | N/A | Maintains | 2 years ago |
Sio Gene Therapies IncSIOX | 2 | Hold | $1.00 | N/A | Downgrades | 2 years ago |
Dicerna Pharmaceuticals IncDRNA | 4 | Buy | $47.00 | N/A | Maintains | 3 years ago |
Adverum Biotechnologies IncADVM | 6 | Hold | $20.00 | N/A | Maintains | 3 years ago |
Avrobio IncAVRO | 1 | Hold | $10.00 | N/A | Maintains | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.